Hepatic veno-occlusive disease (VOD) of the liver is a common complication following high-dose cytotoxic therapy for bone marrow transplantation (BMT). Liver injury is believed to occur following free radical damage to endothelial cells of the sinusoids and small hepatic veins. Glutathione the main antioxidant of the cytosol becomes depleted following chemotherapy. Animal studies have shown that glutamine infusions can maintain glutathione levels and protect against free radical injury. We present two cases of established VOD successfully treated with intravenous glutamine (as dipeptide) and oral vitamin E. Although both cases have possible confounding factors we believe that these give support to the notion that glutamine/vitamin E may have a role in the prophylaxis and treatment of VOD. Further formal trials are indicated. Keywords: veno-occlusive disease; glutamine; vitamin E; bone marrow transplantation Hepatic veno-occlusive disease (VOD) is a leading cause of morbidity and mortality following chemoirradiation therapy for bone marrow transplantation (BMT).
Hepatic veno-occlusive disease (VOD) is a leading cause of morbidity and mortality following chemoirradiation therapy for bone marrow transplantation (BMT).
1,2 Typically occurring within 10-20 days of the start of high-dose treatment, it presents as a triad of painful hepatomegaly, jaundice and fluid retention. 3 Liver biopsies characteristically show subendothelial swelling, narrowing of central veins, dilatation and engorgement of sinusoids, closure of sinusoidal fenestrae and necrosis of hepatocytes in zone 3 of the acinus. A mechanism which may result in this pattern of damage is depletion of glutathione (GSH) allowing hepatocyte and/or endothelial cell injury. The centrilobular zone is relatively depleted of GSH and is the site of glutathione-dependent detoxifying enzymes. Agents used in conditioning regimes can cause GSH depletion, eg BCNU, TBI and bulsulphan, 4 and so prevent effective protection of hepatocytes and endothelial cells from free radicals and activated chemotherapeutic metabolites. 5 Currently treatment of VOD has largely consisted of supportive measures designed to maintain intravascular volume and decrease interstitial oedema. Other treatments used with various measures of success have included recombinant tissue plasminogen activator (tPA), heparin, prostaglandin E, ursodeoxycholic acid and pentoxifylline. Despite these treatments the outcome remains fairly dismal, with no clear role for tPA where mortality still occurs in 20-50% of cases. 6 Therefore, interest is turning to methods of maintaining high glutathione levels (the main antioxidant of hepatic cytosol). Glutamine becomes the rate limiting factor in hepatocyte production of glutathione during periods of catabolic stress. Standard intravenous hyperalimentation regimes do not provide glutamine supplementation; the amino acid itself is unstable in solution and this has led to the recent development of dipeptides such as glycyl-lglutamine and alanyl-l-glutamine which are stable in solution and are hydrolyzed rapidly to l-glutamine.
Recently, dipeptiven (Fresenius, Runcorn, UK) which is a 20% solution of the dipeptide alanyl-l-glutamine, has become available. There is some suggestion that the addition of vitamin E is also helpful in combination with glutamine. 7 Having observed no cases of VOD in a previous BMT study, 8 we decided to treat established VOD with the combination of alanyl-l-glutamine and vitamin E.
We report two cases with established VOD successfully treated with this regimen.
Case 1
A 22-year-old man underwent a peripheral blood stem cell transplant (PBSCT) after busulphan (total dose 12 mg/kg) and cyclophosphamide (total dose 200 mg/kg) for relapsed refractory nodular sclerosing Hodgkin's disease. Prior chemotherapy had consisted of six cycles of LOPP/EVAP, two cycles of miniBeam and six cycles of ABVD. Liver and renal function blood tests were normal and hepatitis screen was negative prior to transplantation.
The conditioning regimen was well tolerated. A neutropenic fever developed on day 5 which was treated with the appropriate antibiotics. He remained well throughout and was discharged on day 15. At this stage he was apyrexial, examination was entirely unremarkable and he had normal liver and renal function.
He was readmitted on day 28 feeling unwell, with peripheral oedema and increasingly short of breath. Examination showed significant weight gain (pre-transplant 63 kg; day 15, 60 kg; day 28, 68 kg), ascites, a right-sided pleural effusion, peripheral oedema and a tender enlarged liver. On specific questioning he admitted to having had abdominal pain over the previous week and an alcohol intake over the previous few days of at least 10 units/day.
Liver function tests were abnormal (Figure 1 ), bilirubin 45 mol/l, alk phos 256 IU/l, asp trans 524 IU/l and albumin 30 g/l. Doppler studies showed hepatomegaly and ascites and all three hepatic veins were of markedly reduced calibre with hardly any detectable flow. Portal venous flow was reduced but in a normal direction. A diagnosis of VOD was made and he was readmitted, fluid restricted and started on a 8-day course of dipeptiven (100 ml daily) intravenously with oral vitamin E (200 mg/day).
He made a rapid clinical improvement. Repeat Doppler studies on day 32 showed small hepatic veins but with easily detectable venous flow with a triphasic pattern. Liver enzymes also improved (Figure 1 ), and he was well enough for discharge on day 38. Further Doppler studies on day 55 were entirely normal. He currently remains well with no liver dysfunction at 8 months, but continues to drink alochol heavily, despite vigorous advice to the contrary.
Case 2
A 43-year-old man underwent a PBSCT with high-dose melphalan conditioning for multiple myeloma. Previous chemotherapy had consisted of cyclophosphamide 4 g/m 2 with prednisolone. His liver and renal function were normal and his hepatitis screen was negative prior to the transplant.
The chemotherapy regimen was well tolerated. He developed a neutropenic fever on day 8 associated with colicky abdominal pain and melena. Hb initially fell to 5.5 g/dl and he was transfused and commenced on the appropriate antibiotics. The fever failed to settle and after a change of antibiotics, he was started on amphotericin B (60 mg/day). Stools were negative for Clostridium difficile and blood cultures failed to isolate an organism.
His temperature and melena settled slowly and he initially made good progress. However, by day 14 he was again deteriorating. On examination he was jaundiced, had developed peripheral oedema, ascitis, tender hepatomegaly and significant weight gain (70.2 kg from 60.5 kg). Doppler studies showed hepatomegaly with narrowed hepatic veins, and a diagnosis of VOD was made.
He was fluid-restricted and commenced on intravenous depeptiven and oral vitamin E (doses as in case 1). His liver enzymes showed a gradual improvement (see graph) and clinically he improved rapidly.
Repeat U/S on day 28 showed a normal liver with normal venous flow, and his liver function remains normal 6 months post-stem cell transplant.
Discussion
Although glutamine is not strictly an essential amino acid, it is considered to be 'conditionally essential' in that endogenous production is adequate under normal conditions but becomes inadequate during severe catabolic illness. It is the most abundant free amino acid in the body accounting for 25% of the amino acid pool in the extracellular fluid and is especially important in providing up to 40% of the energy requirements of the colon and small intestine. Its plasma levels fall rapidly following the inevitable hypercatabolic state following chemotherapy. Although animal studies using oral glutamine initially showed a reduction in mucositis following treatment with 5FU, methotrexate and radiotherapy the effect in humans is more marked in the lower gastrointestinal tract rather than the upper gastrointestinal mucosa.
Glutamine supplementation is not included in i.v. hyperalimentation regimens routinely used since l-glutamine itself is unstable in solution and has limited solubility. Recently dipeptides of l-glutamine have become available providing a more stable and soluble form of glutamine.
Studies using such dipeptides in BMT patients have shown a reduction in the days of hospitalization 9,10 but have been inconsistent in showing a reduction of septic episodes and other endpoints, 11 although a study of 71 patients at this centre clearly showed a reduction in mean and peak endotoxin and pyrexial episodes. 8 As free radical damage to the liver endothelial cells is considered an important mechanism in the initiation of VOD, interest has recently focused on glutathione. Glutathione is a tripeptide consisting of glutamine, cysteine and glycine. Not easily transported across cell membranes, it is synthesized in cell mitochondria and under catabolic stress following chemotherapy, glutamine appears to be the rate limiting amino acid in its production. Glutathione is the major antioxidant of the cytosol, where as vitamin E it is the major antioxidant of the cell membrane (by preventing lipid peroxidation).
Mice pretreated with glutathione monoethylesters (raising the hepatic glutathione levels) were protected from the lethal effects of agents such as monocrotaline, carmustine and cyclophosphamide. 5 Glutathione supplemented nutrition has been shown to preserve hepatic glutathione levels, protect the liver and improve survival in Wistar rats receiving toxic doses of acetaminophen. 12 One previous case report has shown successful treatment of long-standing severe VOD in a patient not responding to either conventional therapy or tPA. 7 In this case, l-glutamine (20 g daily) was given orally, for more than a month, whereas in our patients a short course of 8 and 10 days was given intravenously. Although in the two cases the VOD was not confirmed by liver biopsy, we believe that the diagnosis was firmly made by the combination of classical clinical signs with typical U/S Doppler studies. All the Doppler studies were performed by the same experienced radiologist and were independently assessed by a second consultant. The dramatic improvement seen is therefore not an inter-observer phenomenon. Clinically VOD often occurs in conjunction with other co-existing factors.
In the two cases presented the suggestion of previous alcohol abuse and sepsis with significant melena are two possible confounding factors. Certainly the dramatic response in the LFTs, especially the AST, is in part due to the improvement of alcoholic hepatitis following abstinence from alcohol. However both patients had rapid onset of initial symptoms, classical of VOD and both were clinically deteriorating. As neither case falls into a poor risk category, both having a less than 15% chance of non-spontaneous recovery, their improvement may have been spontaneous. However the rapidity of their clinical recovery together with the dramatic U/S Doppler resolution suggests a role for glutamine and vitamin E. The exact mechanism remains unclear. The increase in glutathione levels would help prevent further cell damage and reduce inflammation, thus accelerating recovery. Whether this would be sufficient to allow healing in a very severe case remains to be seen. However, the results from these two cases certainly suggest that glutamine and vitamin E supplementation may have a beneficial role in hepatic protection from VOD both as prophylactic agents and as possible treatment. Further studies are needed to confirm this interesting observation.
